All articles
Who Should Not Take Mounjaro® For Weight Loss
Reading time:
7 min
Weight loss
Get expert guidance and a personalized care plan designed around you.
Alternatives and Recommendations for Those Unable to Use Mounjaro
Alternative treatments are available for individuals who cannot use Mounjaro® due to contraindications or side effects. These involve other classes of diabetes medications, lifestyle modifications, and, in specific cases, other GLP-1 receptor agonists that might be more suitable. Mochi Health, a comprehensive obesity medicine practice, offers personalized treatment plans that include science-backed medications, providing another pathway to managing obesity safely and effectively.
Dietary advice, physical activity, and ongoing support are crucial in building a treatment plan to achieve and sustain long-term health goals. It's essential to engage in open, honest discussions with healthcare providers to identify the most appropriate and effective treatment options for individual health needs.
Explore other medication here: https://joinmochi.com/medications
Who Can Take Mounjaro® For Weight Loss
For those considering treatment with Mounjaro®, Body Mass Index (BMI) plays a pivotal role in determining eligibility.
The eligibility criteria for tirzepatide-based medications are as follows:
Patients with a BMI of 30 kg/m² or greater (obese)
Patients with a BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbidity such as high blood pressure, high cholesterol, or type 2 diabetes may benefit from these medications. (1,6)
It’s important to note that these medications are most effective as part of a comprehensive weight management plan that includes dietary changes, physical activity, and behavioral adjustments. (1,6) Individuals committed to adopting a healthier lifestyle in combination with medication will see the most beneficial outcomes.
Before initiating treatment, a thorough evaluation by a healthcare provider is essential to assess overall health, potential benefits, and any risks associated with the use of these medications. Personalized care and monitoring will ensure that patients receive the maximum benefit while minimizing potential risks, making this a customer-centric and reassuring approach to weight loss and diabetes management.
Key Considerations Before Starting Mounjaro
It’s important for patients and healthcare providers to understand Mounjaro’s role in aiding in weight loss and its potential benefits and limitations. If you're considering Mounjaro® as part of your weight loss plan, work with your health provider to craft a suitable treatment plan for your health history and individual needs. For those exploring alternatives or seeking additional support managing weight loss, Mochi Health offers a personalized approach to obesity medicine. Learn more about Mochi Health today to discover if you’re eligible for our weight loss program, 1-on-1 provider support, and medications delivered directly to your door, ensuring you receive the comprehensive care you deserve.
References:
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman, C., Cardona, G. R., Urva, S., Emmerson, P. J., Holst, J. J., D'Alessio, D. A., Coghlan, M. P., Rosenkilde, M. M., Campbell, J. E., & Sloop, K. W. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight, 5(17), e140532. https://europepmc.org/article/pmc/pmc7526454
Karrar HR, Nouh MI, Nouh YI, Nouh MI, Khan Alhindi AS, Hemeq YH, Aljameeli AM, Aljuaid JA, Alzahrani SJ, Alsatami AA, Alkredees MA, Almuqati AO, Abanmi SN, Alshehri AM. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. Cureus. 2023 Sep 27;15(9):e46091. https://www.cureus.com/articles/170540#!/
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., Seeley, R. J., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular metabolism, 30, 72–130. https://www.sciencedirect.com/science/article/pii/S2212877819309135?via%3Dihub
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 327(6), 534–545. https://jamanetwork.com/journals/jama/fullarticle/2788781
Food and Drug Administrator. (n.d.-b). MOUNJAROTM (tirzepatide) injection, for subcutaneous use. Access Data FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
This post was written by our team of health writers for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider for personalized guidance regarding your health. Ozempic®, Wegovy®, Mounjaro®, and Zepbound® and their delivery device are registered trademarks. Mochi Health is a telehealth clinic that offers prescriptions for these products by medical necessity only as determined by a licensed health provider.
Share this post
Weight loss
More articles
Read next
For iOS & Android
